Roivant Sciences (ROIV) Common Equity (2020 - 2026)

Roivant Sciences (ROIV) has 7 years of Common Equity data on file, last reported at $4.5 billion in Q1 2026.

• Quarterly Common Equity fell 3.42% year-over-year to $4.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 billion (down 3.42% YoY) and the FY2026 annual result came in at $4.5 billion, down 3.42% from the prior year.
• Common Equity retreated to $4.5 billion in Q1 2026, from $5.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $6.6 billion in Q4 2023 to a low of $1.3 billion in Q3 2023.
• A 5-year average of $3.8 billion and a median of $4.7 billion in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity plunged 37.65% — and 2023, when it jumped 361.38%.
• Tracing ROIV's Common Equity over 5 years: stood at $1.4 billion in 2022, then surged by 361.38% to $6.6 billion in 2023, then decreased by 15.93% to $5.5 billion in 2024, then dropped by 10.15% to $5.0 billion in 2025, then decreased by 8.98% to $4.5 billion in 2026.
• The last three Common Equity figures came in at $4.5 billion (Q1 2026), $5.0 billion (Q4 2025), and $4.8 billion (Q3 2025), per Business Quant data.